BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00

Palvella Therapeutics (NASDAQ:PVLA) had its price objective lifted by research analysts at BTIG Research from $192.00 to $215.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective would suggest a potential upside of 44.94% from the stock’s previous close.

Several other equities research analysts have also recently commented on PVLA. Stifel Nicolaus set a $250.00 price target on Palvella Therapeutics in a report on Tuesday. Truist Financial set a $210.00 target price on Palvella Therapeutics in a research note on Tuesday. Raymond James Financial reiterated a “strong-buy” rating and set a $193.00 price target on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Oppenheimer reissued an “outperform” rating and issued a $200.00 price objective on shares of Palvella Therapeutics in a report on Monday, December 15th. Finally, HC Wainwright raised their price objective on shares of Palvella Therapeutics from $200.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $176.44.

Palvella Therapeutics Trading Up 15.3%

Shares of NASDAQ PVLA opened at $148.34 on Wednesday. The stock has a market cap of $1.76 billion, a PE ratio of -56.40 and a beta of -0.16. Palvella Therapeutics has a 12-month low of $18.23 and a 12-month high of $151.18. The company has a 50-day moving average of $93.82 and a 200 day moving average of $79.34.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Archer Investment Corp acquired a new stake in Palvella Therapeutics in the third quarter valued at approximately $28,000. Group One Trading LLC raised its holdings in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at $36,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter worth $37,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics News Roundup

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 / late‑stage clinical news has driven investor enthusiasm — coverage and headlines about a late‑stage win for Palvella’s lead asset are cited as a major momentum driver. Palvella Therapeutics shares surge on positive Phase 3 trial results
• Positive Sentiment: HC Wainwright materially raised multi‑year EPS forecasts and bumped its price target to $255 (from $200), and the firm retains a Buy — analyst upgrades and a hawkish target boost sentiment and institutional interest. Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright
• Positive Sentiment: Other firms have increased targets (Mizuho $250, BTIG $215, Chardan $210), signaling broad analyst conviction and adding buying pressure from funds tracking upgrades. Chardan Capital Boosts Palvella Therapeutics Price Target to $210.00
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 to raise roughly $200M (plus a 30‑day option on 240k shares). The proceeds will fund QTORIN programs and R&D (cash runway positive), but the issuance dilutes current shareholders and adds near‑term supply. Palvella Therapeutics Announces Pricing of Upsized Public Offering
• Negative Sentiment: Short interest rose ~22% in February to about 1.67M shares (~17.8% of float) with ~5.5 days to cover; sizable short positions can pressure the stock if trial/clinical timelines slip, though they can also amplify rallies in the near term. Insider sales have also been reported, which some investors view negatively. (No single article link provided in the feed.)

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.